PRODUCT SPECIFICATION

iLite® TNF-alpha Assay Ready Cells
REF: BM3044
For research use only. Not for use in diagnostic procedures.

DESCRIPTION

iLite® TNF-alpha Assay Ready Cells are a genetically engineered
reporter gene cell line of human erythroleukemic origin (K562)
responsive to tumor necrosis factor alpha (TNF-alpha), resulting in thespecific expression of Firefly Luciferase. Normalization of cell count andserum matrix effects is obtained by a second reporter gene, a Renilla
Luciferase reporter gene construct, under control of a constitutivepromotor.

CONTENT1.5 mL of Assay Ready Cells suspended in RPMI 1640 with 20% heat
inactivated fetal bovine serum (FBS), 10% glycerol and 2.5% dimethyl
sulfoxide (DMSO).

RECEIPT AND
STORAGE

Upon receipt confirm that adequate dry-ice is present, and the cells arefrozen. Immediately transfer to -80 C storage. Cells should be stored at-80 C (do not store at any other temperature) and are stable assupplied until the expiry date shown. Cells should be diluted immediately
after thawing and should be used within 30 min.

BACKGROUND

TNF-alpha promotes inflammatory responses, which in turn contribute to theclinical symptoms associated with many inflammatory disorders, including
rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis andrefractory asthma. (1) These diseases are in many cases treated with TNF-alphainhibitors, such as infliximab, adalimumab, or etanercept to mention a few.
Prolonged therapies with these TNF-alpha inhibitors may lead to developmentof neutralizing antibodies (NAbs), which may counteract the TNF-alphaantagonist activity of the inhibitors. (2)APPLICATION

The iLite® TNF-alpha Assay Ready Cells can be used for measurements offunctional TNF-alpha, TNF-alpha inhibitor activity and presence of neutralizingantibodies to TNF-alpha inhibitors. (3,4)

Application Notes for the following assays are available:•••

RELATEDPRODUCTS

Quantification of functional TNF-alpha (LABEL-DOC-0479)
Quantification of TNF-alpha inhibitor activity (LABEL-DOC-0480)
Determination of neutralizing antibodies against TNF-alpha inhibitor(LABEL-DOC-0482)

REF

Product name

BM3132iLite® Diluent A

BM3133iLite® TNF-alpha (16 ng/mL)

BM3134iLite® Diluent B

BM3135iLite® Reagent BLANK

Svar Life Science AB
Lundavägen 151

P.O. Box 50117

info@svarlifescience.com

SE-212 24 Malmö

SE-202 11 Malmö+46 40 53 76 00

SwedenSwedenLABEL-DOC-0355, 3.0
Page 1/2

PRODUCT SPECIFICATIONREFERENCES

BM3136iLite® Infliximab NAb positive control

BM3139iLite® Diluent C

BM3159iLite® Adalimumab NAb positive control

BM3177iLite® Etanercept NAb positive control

1.

2.
3.
4.

Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms andemerging therapeutic strategies. Nat Rev Rheumatol. 2016 Jan;12(1):4962.
Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF
inhibitors: implications for rheumatoid arthritis treatment. Nat RevRheumatol. 2017 Nov 21;13(12):707-718.
Lallemand C, Tovey MG. et al. Reporter gene assay for the quantificationof the activity and neutralizing antibody response to TNF-alpha antagonists.
J Immunol Meth. 2011, 373: 229-239.
Pavlov I, Delgado JC et al. Clinical laboratory application of a reporter-geneassay for measurement of functional activity and neutralizing antibody
response to infliximab. Clinica Chimica Acta. 2016, 453:147-153.

SYMBOLS ON
LABELPRECAUTIONS

Lot number

Temperature limitation

Catalogue number

Biological risk

Use byManufacturer

For research use only. This product is intended for professional laboratory
research use only. The data and results originating from using the productshould not be used either in diagnostic procedures or in human therapeutic
applications.
iLite® TNF-alpha Assay Ready Cells are a stable transfected cell line of humanorigin classified as a Class 1 Genetically Modified Microorganism. They should
be handled in accordance with EU directive (2009/41/EC) and disposed of in alicensed contained-use facility in accordance with these regulations. When usedin accordance with the manufacturer’s product specification, the requirementsof EU directive 2009/41/EC on the contained use of genetically modified
microorganisms are deemed to have been met.
Residues of chemicals and preparations generally considered as biohazardous
waste should be inactivated prior to disposal by autoclaving or using bleach. Allsuch materials should be disposed of in accordance with established safetyprocedures.

PROPRIETARYINFORMATION

In accepting delivery of iLite® Assay Ready Cells the recipient agrees not tosub-culture these cells, attempt to sub-culture them or to give them to a third
party, and only to use them directly in assays. iLite® cell-based products arecovered by patents which is the property of Svar Life Science AB and any
attempt to reproduce the delivered iLite® Assay Ready Cells is an infringementof these patents.

Svar Life Science AB
Lundavägen 151

P.O. Box 50117

info@svarlifescience.com

SE-212 24 Malmö

SE-202 11 Malmö+46 40 53 76 00

SwedenSwedenLABEL-DOC-0355, 3.0
Page 2/2